tumorsMalignant tumoursMalignant tumours2224-50572587-6813Rosoncoweb10.18027/2224-5057-2025-048tumors-1477Research ArticleРЕЗОЛЮЦИЯRESOLUTIONРезолюция по итогам экспертного совета по подходам к диагностике и терапии RET-позитивного немелкоклеточного рака лёгкого в РФResolution on the results of the expert council on approaches to diagnostics and therapy of RET-positive non-small cell lung cancer in the Russian FederationРедакционнаястатьяEditorialArticle2025240820251527376Copyright © Редакционная с., 20252025Редакционная с.Editorial a.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.malignanttumors.org/jour/article/view/1477
.
.
ReferencesСостояние онкологической помощи населению России в 2023 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой 2023. М. : МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. − илл. – 262 с.The state of cancer care for the population of Russia in 2023. Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024.262 p. (In Russ.)Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М. : МНИОИ им. П.А. Герцена − филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. – илл. – 276 с.Malignant tumors in Russia in 2023 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shachzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2024.276 p. (In Russ.)Рак легкого. Под ред. К. К. Лактионова, В. В. Бредера — М. : «ГРАНАТ», 2020.Lung cancer. Eds.: K.K. Laktionov, V.V. Breder — М. : “GRANAT”, 2020 (In Russ.)Лактионов К.К., Артамонова Е.В., Бредер В.В. и соавт. Немелкоклеточный рак легкого. Практические рекомендации RUSSCO, часть 1.1. Злокачественные опухоли 2024;14(3s2):65–104. doi: 10.18027/2224-5057-2024-14-3s2-1.1-04Laktionov K.K., Artamonova E.V., Breder V.V., et al. Non-small cell lung cancer. Practical recommendations RUSSCO, part 1.1. Zlokachestvennie opuholi = Malignant Tumors 2024;14(3s2):65–104 (In Russ.). doi: 10.18027/2224-5057-2024-14-3s2-1.1-04 (In Russ.)Latysheva N.S., Babu M.M. Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Res 2016;44(10):4487–503. doi: 10.1093/nar/gkw282Latysheva N.S., Babu M.M. Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Res 2016;44(10):4487–503. doi: 10.1093/nar/gkw282Subbiah V., Cote G.J. Advances in targeting RET-dependent cancers. Cancer Discov 2020;10(4):498–505. doi: 10.1158/2159-8290.CD-19-1116Subbiah V., Cote G.J. Advances in targeting RET-dependent cancers. Cancer Discov 2020;10(4):498–505. doi: 10.1158/2159-8290.CD-19-1116Agrawal N., Jiao Y., Sausen M., et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013;98(2):E364–9. doi: 10.1210/jc.2012-2703Agrawal N., Jiao Y., Sausen M., et al. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS. J Clin Endocrinol Metab 2013;98(2):E364–9. doi: 10.1210/jc.2012-2703Al-Jundi M., Thakur Sh., Gubbi S., Klubo-Gwiezdzinska J. Novel targeted therapies for metastatic thyroid cancer-a comprehensive review. Cancers (Basel) 2020;12(8):2104. doi: 10.3390/cancers12082104Al-Jundi M., Thakur Sh., Gubbi S., Klubo-Gwiezdzinska J. Novel targeted therapies for metastatic thyroid cancer-a comprehensive review. Cancers (Basel) 2020;12(8):2104. doi: 10.3390/cancers12082104Gautschi O., Milia J., Filleron T., et al. Targeting RET in patients with RET-Rearranged lung cancers: results from the global, multicenter RET registry. J Clin Oncol 2017;35(13):1403–1410. doi: 10.1200/JCO.2016.70.9352Gautschi O., Milia J., Filleron T., et al. Targeting RET in patients with RET-Rearranged lung cancers: results from the global, multicenter RET registry. J Clin Oncol 2017;35(13):1403–1410. doi: 10.1200/JCO.2016.70.9352Li T., Kung H.J., Mack P.C., Gandara D.R. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013;31(8):1039–49. doi: 10.1200/JCO.2012.45.3753Li T., Kung H.J., Mack P.C., Gandara D.R. Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol 2013;31(8):1039–49. doi: 10.1200/JCO.2012.45.3753Результаты проекта АНО НООП «Таргетное секвенирование ткани опухоли больных немелкоклеточным неплоскоклеточным раком легкого в Российской Федерации». Доступно по: https://77.37.209.172/archive/?id=NKZvNa502x0Results of the ANO NOOPS project "Targeted Sequencing of Tumor Tissue in Patients with Non-Small Cell Non-Squamous Lung Cancer in the Russian Federation". Available at: https://77.37.209.172/archive/?id=NKZvNa502x0 (In Russ.)Drilon A., Subbiah V., Gautschi O., et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol 2023;41(2):385–394. doi: 10.1200/JCO.22.00393. Erratum in: J Clin Oncol 2023 Nov 1;41(31):4941. doi: 10.1200/JCO.23.01849Drilon A., Subbiah V., Gautschi O., et al. Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I/II trial. J Clin Oncol 2023;41(2):385–394. doi: 10.1200/JCO.22.00393. Erratum in: J Clin Oncol 2023 Nov 1;41(31):4941. doi: 10.1200/JCO.23.01849Subbiah V., Gainor J.F., Oxnard G.R., et al. Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial. Clin Cancer Res 2021;27(15):4160–4167. doi: 10.1158/1078-0432.CCR-21-0800Subbiah V., Gainor J.F., Oxnard G.R., et al. Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial. Clin Cancer Res 2021;27(15):4160–4167. doi: 10.1158/1078-0432.CCR-21-0800ClinicalTrials.gov identifier NCT04194944. A Study of Selpercatinib (LY3527723) in Participants with Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431). US Clinical Trials Registry, 2025. Available at: https://ichgcp.net/clinical-trials-registry/NCT04194944ClinicalTrials.gov identifier NCT04194944. A Study of Selpercatinib (LY3527723) in Participants with Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431). US Clinical Trials Registry, 2025. Available at: https://ichgcp.net/clinical-trials-registry/NCT04194944Zhou C., Solomon B., Loong H.H., et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med 2023;389(20):1839–1850. doi: 10.1056/NEJMoa2309457Zhou C., Solomon B., Loong H.H., et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med 2023;389(20):1839–1850. doi: 10.1056/NEJMoa2309457Loong H.H.F., Goto K., Solomon B.J., et al. Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC. ESMO Congress 2023, LBA4Loong H.H.F., Goto K., Solomon B.J., et al. Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC. ESMO Congress 2023, LBA4Lee A.T.M., Ou S.I. LIBRETTO-431: Confirming the superiority of selpercatinib to chemotherapy and the lack of efficacy of immune checkpoint inhibitors in advanced RET fusion-positive (RET +) NSCLC, another unique never-smoker predominant molecular subtype of NSCLC. Lung Cancer (Auckl) 2024;15:75–80. doi: 10.2147/LCTT.S460147Lee A.T.M., Ou S.I. LIBRETTO-431: Confirming the superiority of selpercatinib to chemotherapy and the lack of efficacy of immune checkpoint inhibitors in advanced RET fusion-positive (RET +) NSCLC, another unique never-smoker predominant molecular subtype of NSCLC. Lung Cancer (Auckl) 2024;15:75–80. doi: 10.2147/LCTT.S460147Soria J.C., Ohe Y., Vansteenkiste J., et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378(2):113–125. doi: 10.1056/NEJMoa1713137Soria J.C., Ohe Y., Vansteenkiste J., et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018;378(2):113–125. doi: 10.1056/NEJMoa1713137Mok T., Camidge D.R., Gadgeel S.M., et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 2020;31(8):1056–1064. doi: 10.1016/j.annonc.2020.04.478Mok T., Camidge D.R., Gadgeel S.M., et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann Oncol 2020;31(8):1056–1064. doi: 10.1016/j.annonc.2020.04.478Camidge D.R., Bang Y.J., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13(10):1011–9. doi: 10.1016/S1470-2045(12)70344-3.Camidge D.R., Bang Y.J., Kwak E.L., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13(10):1011–9. doi: 10.1016/S1470-2045(12)70344-3.
The authors declare that there are no conflicts of interest present.